Search for European Projects

12 European Projects Found

Searched on 125080 European Projects

 FINISHED 

mTOR pathophysiology in rare human diseases (RariTOR)

Start date: Feb 1, 2015, End date: Jan 31, 2020,

The mammalian Target Of Rapamycin (mTOR) is a master regulator of growth. mTOR is a protein kinase that exists in two distinct complexes in the cell and transduces virtually all anabolic signals from the environment: nutrients, such as glucose and amino acids, growth factor peptides, such as insulin and insulin like growth factors, oxygen, mitochondrial metabolites, energy status. mTOR is required ...
Read Project

 1

 FINISHED 

Glomerulonephritis and Focal Segmental Glomerulosclerosis as a Model to Investigate the Link between Inflammation and Kidney Disease: From Basic Mechanisms to Clinical Application (TARGET GLOMDIS)

Start date: Mar 1, 2013, End date: Feb 28, 2018,

"Rapidly progressive glomerulonephritis (RPGN) and focal and segmental glomerulosclerosis (FSGS) are severe kidney diseases responsible for irreversible renal failure, which is a major risk factor for mortality. Despite the aggressiveness of immunosuppressive protocols applied, treatments against RPGN have limited effectiveness. Similarly, there is no specific treatment for FSGS. We built this res ...
Read Project

 1

 FINISHED 

Phase I/II ex vivo gene therapy clinical trial for recessive dystrophic epidermolysis bullosa using skin equivalent grafts genetically corrected with a COL7A1-encoding SIN retroviral vector (GENEGRAFT)

Start date: Mar 1, 2011, End date: Dec 31, 2017,

RDEB is one of the most severe rare genetic skin diseases of children and adults characterized by skin blistering resulting from lack of expression of type VII collagen. There is no treatment for this life-threatening disease. In March 2009, we obtained the orphan drug designation for the Medicinal product: “Skin equivalent graft genetically corrected with a COL7A1-encoding SIN retroviral vecto ...
Read Project

 10

 FINISHED 

Management of Hypotension In the Preterm Extremely Low Gestational Age Newborn (THE HIP TRIAL)

Start date: Oct 1, 2010, End date: Sep 30, 2017,

Assuming an annual birth rate of 10.25 births/1,000 population approximately 25,000 Extremely Low Gestational Age Newborns are born every year in the EU. Conservative figures estimate that approximately half of all these babies will develop low blood pressure and require treatment. However, no uniform criteria exist to define hypotension and the evidence to support our current management strategie ...
Read Project

 17

 FINISHED 

European Consortium for High-Throughput Research in Rare Kidney Diseases (EURENOMICS)

Start date: Oct 1, 2012, End date: Sep 30, 2017,

EURenOmics will integrate several established consortia devoted to rare kidney diseases with eminent need and potential for diagnostic and therapeutic progress (i.e. steroid resistant nephrotic syndrome, membranous nephropathy, tubulopathies, complement disorders such a haemolytic uraemic syndrome, and congenital kidney malformations). The Consortium has access to the largest clinical cohorts asse ...
Read Project

 29

 FINISHED 

Development of an innovative paediatric formulation of an antiepileptic agent for the treatment of absence epilepsy in children (KIEKIDS)

Start date: Oct 1, 2011, End date: Mar 31, 2017,

The KIEKIDS project is dedicated to the development of an innovative paediatric formulation of an antiepileptic agent for a safe alternative treatment of absence epilepsy in children.Development of such an age-appropriate formulation is regarded by The European Medicines Agency (EMA) to be amongst one of highest priorities for the treatment of absence seizures, using a drug with identified and doc ...
Read Project

 4

 FINISHED 

Improving beta-cell function and identification of diagnostic biomarkers for treatment monitoring in diabetes (IMIDIA)

Start date: Feb 1, 2010, End date: Sep 30, 2015,

An absolute or relative loss of beta-cell mass and function underlie the development of type I and type 2 diabetes.Preventing beta-cell demise or restoring their number and function is a major therapeutic goal. However,development of novel diagnostic and prognostic tools, and of novel therapeutic modalities, is hampered by the limited knowledge of the molecular pathways that control beta-cell demi ...
Read Project

 23

 FINISHED 

Primary immunodeficiency diseases as models for the study of the immune system (PIDIMMUN)

Start date: Jul 1, 2010, End date: Jun 30, 2015,

The study of primary immunodeficiency diseases has provided significant insights into how the immune system works. This notably includes in vivo immune responses to microorganisms, pathogens or opportunistic agents and in vivo control of reactivity to self, in relation to the identification of specific gene mutations. Hence, some of the key factors of the immune system have been unraveled. In this ...
Read Project

 1

 FINISHED 

The B cell memory program: cell fate determinants and functional diversity of B cell subsets (Memo-B)

Start date: Jul 1, 2010, End date: Jun 30, 2015,

B cells are responsible for the humoral arm of the immune response and most successfulvaccines in humans are antibody-based. Depending on the pathogen, specific B cell subsets aremobilized and a variety of innate, intermediate or adaptive responses are produced. In somecases these responses generate memory in anticipation of a re-encounter with the same pathogen.B cells can also present antigens t ...
Read Project

 1

 FINISHED 

Impact of IL-7 and IFNa on nTreg development (3ITD)

Start date: Feb 1, 2011, End date: Jan 31, 2013,

"In developed countries, most HIV-infected patients are under highly active antiretroviral therapy (HAART). However, despite controlled viral replication, the immune reconstitution often remains incomplete, probably due to a poor reconstitution of thymic production. Apart its role in educating a diverse repertoire of conventional T-cells, the thymus also produces natural regulatory T-cells (nTreg) ...
Read Project

 1

 FINISHED 

The role of host cell actin cytoskeleton in invasion by Apicomplexa parasites (API-INVASION)

Start date: Dec 1, 2009, End date: Nov 30, 2012,

"Members of the Apicomplexa phylum are obligatory intracellular parasites many of which being important human pathogens. Plasmodium sp., the etiological agent of malaria is the most devastating but Toxoplasma gondii can be severe in both immune-compromised individuals where it causes encephalitis or pneumonia and infect fetuses. These parasites invade host cells by transforming into specialized st ...
Read Project

 1

 FINISHED 

Cell growth control by nutrients (NUTRITION)

Start date: Oct 1, 2008, End date: Sep 30, 2012,

Mammalian Target Of Rapamycin (mTOR) is an evolutionary conserved protein kinase that integrates signals from growth factors, nutrients and cellular energy status to regulate cell proliferation, survival, growth and metabolism. mTOR functions have been inferred so far by employing rapamycin, an inhibitor that has therapeutical uses as immunosuppressive and anti cancer agent. However rapamycin is n ...
Read Project

 1